Drug Discovery & Pharmaceuticals

RSS

Chemists find new way to make enzymes do a non-natural reaction

Princeton chemists have found a way to make a naturally occurring enzyme take on a new, artificial role, which has significant implications for modern chemistry, including pharmaceutical production.

22 Jun 2018

Scientists discover the molecular trigger of necroptosis

Researchers have uncovered a trigger for an immune-related cell death pathway called necroptosis. The discovery could be used to develop new treatments for cancer and immune disorders.

21 Jun 2018

Protein Data Bank at Rutgers impacts research, education and drug discovery

When Jimmy Carter was diagnosed with end-stage metastatic melanoma in 2015, he began taking a drug developed in part using 3D molecular data.

21 Jun 2018

Distek, Inc. launches new product that extends the capabilities of the symphony 7100

Distek, Inc. announced today the release of their small volume conversion kit for the symphony 7100 bathless dissolution tester,

20 Jun 2018

Microbiotica partners with University of Adelaide to develop defined bacterial product for ulcerative colitis

Microbiotica, a leading player in microbiome-based therapeutics, today announced that it has entered into an agreement with University of Adelaide as part of its program to develop a defined bacterial product for ulcerative colitis (UC). Financial details have not been disclosed.

19 Jun 2018

Chemists invent new method for remote chiral induction

Chemists at Scripps Research have addressed one of the most formidable challenges in synthetic chemistry by inventing a method for "enantioselective remote meta-CH activation," which enables the making of chiral molecules that were previously difficult or impossible to synthesize.

19 Jun 2018

Scientists could build better drugs by learning from bacteria-derived molecules

Bacteria found in soil may harbor a potential game-changer for drug design. A new study by Scripps Research, published today in Nature Communications, suggests scientists could build better drugs by learning from bacteria-derived molecules called thiocarboxylic acids.

19 Jun 2018

Novel compound as effective as FDA-approved antibiotics for treating deadly infections

Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.

18 Jun 2018

Award granted to Neem Biotech to develop antimicrobial intervention for chronic lung infections

Neem are working on a novel approach to antimicrobial resistance, which involves preventing the formation of and disrupts mature biofilms that are produced by bacteria such as Pseudomonas aeruginosa and Staphylococcus aureus.

From Neem Biotech 18 Jun 2018

New collaboration integrates Intabio's Blaze solution with Bruker's mass spectrometers

Intabio, Inc., announced today that it has entered into a collaboration with Bruker to accelerate integration of Intabio's Blaze™ solution with Bruker's high resolution mass spectrometers.

From Bruker Life Sciences Mass Spectrometry 14 Jun 2018

Sharks could inspire new type of surface that would attack harmful bacteria

Sharks are often the subject of TV specials or news stories focusing on their attacks on humans. But scientists are finding that sharks could inspire a new type of surface that would attack bacteria, helping humans instead of hurting them.

14 Jun 2018

Scientists discover vaccine that may rapidly fight cholera-causing bacteria

A tricked-out cholera vaccine starts protecting against the deadly disease within a day, experiments in rabbits suggest.

14 Jun 2018

Unique project to develop fully-automated technology for faster and effective drug discovery

A unique project to develop technology to drive fast and effective drug discovery was announced today by Business Secretary Greg Clark. Based at the Rosalind Franklin Institute in Harwell, Oxfordshire, this new project will pioneer fully-automated hands-free molecular discovery to produce new drugs up to ten times faster and transform the UK’s pharmaceutical industry.

13 Jun 2018

AbCellera and Denali collaborate to discover new antibodies to fight neurodegenerative diseases

AbCellera Biologics Inc. today announced the successful completion of the first phase of its collaboration with Denali Therapeutics Inc.

12 Jun 2018

Combination of antibodies shown to cause rheumatoid arthritis

Researchers have shown that severe inflammation and joint damage in rheumatoid arthritis (RA) is primarily caused by a combination of different antibodies.

12 Jun 2018

Translate Bio collaborates with Sanofi to develop mRNA vaccines for infectious diseases

Translate Bio, a clinical-stage messenger RNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, announced today a multi-year research and development collaboration and exclusive licensing agreement with Sanofi Pasteur, the vaccines global business unit of Sanofi, to develop mRNA vaccines for up to five undisclosed infectious disease pathogens.

11 Jun 2018

Research drug may one day be novel treatment for systemic inflammatory response syndrome

When trauma spills the contents of our cell powerhouses, it can evoke a potentially deadly immune response much like a severe bacterial infection.

11 Jun 2018

International experts agree on need for human-relevant research to improve drug discovery

The average pre-approval cost of research and development for a successful drug is estimated to be US$2.6 billion and the number of new drugs approved per billion US dollars spent has halved roughly every 9 years since 1950.

8 Jun 2018

Neem Biotech present biofilm disruptor at BIO Boston 2018, to minimise antimicrobial resistance

Neem Biotech, a Wales based pharmaceutical biotech working in the field of novel antimicrobial research and development will present details of the company’s approach to minimising antimicrobial resistance through biofilm disruption at BIO Boston 2018.

From Neem Biotech 7 Jun 2018

Microbiotica collaborates with Genentech to develop drugs for IBD

Microbiotica, a leading player in microbiome-based therapeutics spun out of the Wellcome Sanger Institute, today announced that it has entered into a multi-year strategic collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialize biomarkers, targets and medicines for inflammatory bowel disease.

6 Jun 2018

Drug Discovery & Pharmaceuticals

Chemists find new way to make enzymes do a non-natural reaction

Scientists discover the molecular trigger of necroptosis

Protein Data Bank at Rutgers impacts research, education and drug discovery

Distek, Inc. launches new product that extends the capabilities of the symphony 7100

Microbiotica partners with University of Adelaide to develop defined bacterial product for ulcerative colitis

Chemists invent new method for remote chiral induction

Scientists could build better drugs by learning from bacteria-derived molecules

Novel compound as effective as FDA-approved antibiotics for treating deadly infections

Award granted to Neem Biotech to develop antimicrobial intervention for chronic lung infections

New collaboration integrates Intabio's Blaze solution with Bruker's mass spectrometers

Sharks could inspire new type of surface that would attack harmful bacteria

Scientists discover vaccine that may rapidly fight cholera-causing bacteria

Unique project to develop fully-automated technology for faster and effective drug discovery

AbCellera and Denali collaborate to discover new antibodies to fight neurodegenerative diseases

Combination of antibodies shown to cause rheumatoid arthritis

Translate Bio collaborates with Sanofi to develop mRNA vaccines for infectious diseases

Research drug may one day be novel treatment for systemic inflammatory response syndrome

International experts agree on need for human-relevant research to improve drug discovery

Neem Biotech present biofilm disruptor at BIO Boston 2018, to minimise antimicrobial resistance

Microbiotica collaborates with Genentech to develop drugs for IBD

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News